NZ708371A - Methods for treating pruritus - Google Patents

Methods for treating pruritus

Info

Publication number
NZ708371A
NZ708371A NZ708371A NZ70837113A NZ708371A NZ 708371 A NZ708371 A NZ 708371A NZ 708371 A NZ708371 A NZ 708371A NZ 70837113 A NZ70837113 A NZ 70837113A NZ 708371 A NZ708371 A NZ 708371A
Authority
NZ
New Zealand
Prior art keywords
methods
treating pruritus
pruritus
treating
nalbuphine
Prior art date
Application number
NZ708371A
Other languages
English (en)
Inventor
Thomas Sciascia
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/715,625 external-priority patent/US8637538B1/en
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of NZ708371A publication Critical patent/NZ708371A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
NZ708371A 2012-12-14 2013-12-13 Methods for treating pruritus NZ708371A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737488P 2012-12-14 2012-12-14
US13/715,625 US8637538B1 (en) 2012-12-14 2012-12-14 Methods for treatment of pruritis
PCT/US2013/075096 WO2014093871A1 (en) 2012-12-14 2013-12-13 Methods for treating pruritus

Publications (1)

Publication Number Publication Date
NZ708371A true NZ708371A (en) 2020-05-29

Family

ID=50935003

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ708371A NZ708371A (en) 2012-12-14 2013-12-13 Methods for treating pruritus

Country Status (13)

Country Link
EP (1) EP2931279B1 (enExample)
JP (4) JP2016506398A (enExample)
KR (3) KR20150093702A (enExample)
CN (2) CN110585209A (enExample)
AU (2) AU2013359017B2 (enExample)
BR (1) BR112015013984A2 (enExample)
CA (1) CA2892393C (enExample)
ES (1) ES2984559T3 (enExample)
MX (1) MX2015007518A (enExample)
NZ (1) NZ708371A (enExample)
RU (1) RU2015128265A (enExample)
WO (1) WO2014093871A1 (enExample)
ZA (2) ZA201504229B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法
WO2015192071A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
TW201725041A (zh) * 2016-01-04 2017-07-16 懷特生技新藥股份有限公司 治療皮膚癢之醫藥組合物
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
CA3017374A1 (en) * 2016-03-21 2017-09-28 Trevi Therapeutics, Inc. Treatment of uremic pruritus
WO2018081273A1 (en) * 2016-10-25 2018-05-03 Trevi Therapeutics, Inc. Treatment of prurigo nodularis
KR102329377B1 (ko) * 2017-02-03 2021-11-19 가부시키가이샤 도요 신야쿠 고형 제제
CN118512451A (zh) * 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535687A (zh) * 1996-11-25 2004-10-13 ������������ʽ���� 止痒药物
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
LT2425821T (lt) * 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
CA2566217A1 (en) * 2004-06-03 2005-12-15 Jonathan J. Burbaum Pharmaceutical compositions for the treatment of pruritus
CA2620224C (en) 2005-08-24 2015-11-24 Penwest Pharmaceuticals Company Sustained release formulations of nalbuphine
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法

Also Published As

Publication number Publication date
HK1215541A1 (en) 2016-09-02
ZA201906339B (en) 2021-07-28
AU2013359017B2 (en) 2018-05-10
CA2892393C (en) 2021-06-08
MX2015007518A (es) 2016-03-01
CN110585209A (zh) 2019-12-20
JP7072280B2 (ja) 2022-05-20
AU2018214098A1 (en) 2018-08-30
KR20210050585A (ko) 2021-05-07
JP6823857B2 (ja) 2021-02-03
RU2015128265A (ru) 2017-01-25
AU2018214098B2 (en) 2019-04-18
JP2021020947A (ja) 2021-02-18
WO2014093871A1 (en) 2014-06-19
CN104981246A (zh) 2015-10-14
ZA201504229B (en) 2021-07-28
JP2016506398A (ja) 2016-03-03
EP2931279B1 (en) 2024-03-20
JP2019131588A (ja) 2019-08-08
KR20220044385A (ko) 2022-04-07
BR112015013984A2 (pt) 2017-07-11
CA2892393A1 (en) 2014-06-19
AU2013359017A1 (en) 2015-06-11
ES2984559T3 (es) 2024-10-29
EP2931279A4 (en) 2016-05-11
KR20150093702A (ko) 2015-08-18
JP2022105095A (ja) 2022-07-12
EP2931279A1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
MX2015007518A (es) Metodos para tratar el prurito.
SG11201506944WA (en) Betaine compounds as additives for fuels
IL245353B (en) Converted benzamides for the treatment of arthropods
EP2970964B8 (en) Exon skipping compositions for treating muscular dystrophy
AP3859A (en) Heterocyclyl compounds as MEK inhibitors
GB201416353D0 (en) Additive manfacturing
IN2015DN00598A (enExample)
EP2970603A4 (en) MODIFIED TONER-BASED ADDITIVE FOR ASPHALT-BASED COMPOSITIONS
ZA201308947B (en) Substituted pyridopyrazines as novel syk inhibitors
MX370649B (es) Proceso para la preparacion de teneligliptina.
GB201318163D0 (en) Refrigerant additive
IL239153A0 (en) Substitute pyridopyrazine as an inhibitor
MX2015001506A (es) Proceso e intermediarios para preparar inhibidores de integrasa.
SG11201509341VA (en) Fuel additive composition
IN2014DN08777A (enExample)
ZA201405227B (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
IN2014DN06738A (enExample)
IN2015DN00725A (enExample)
IN2014DN10780A (enExample)
GB201322176D0 (en) Fuel additive composition
MY171860A (en) Method for purifying a crude pnpnh compound
MX369174B (es) Proceso para la preparación de un compuesto.
GB2507675B (en) Fuel additive composition
ZA201507439B (en) Promoter compositions
IN2015KN00386A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 DEC 2021 BY COMPUTER PACKAGES INC

Effective date: 20201118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 DEC 2022 BY COMPUTER PACKAGES INC

Effective date: 20211117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 DEC 2023 BY COMPUTER PACKAGES INC

Effective date: 20221117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 DEC 2024 BY COMPUTER PACKAGES INC

Effective date: 20231117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 DEC 2025 BY COMPUTER PACKAGES INC

Effective date: 20241117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 DEC 2026 BY COMPUTER PACKAGES INC

Effective date: 20251126